One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Pharmaceutical Contract Manufacturing Global Market

製薬受託製造市場ー業界洞察、主要プレーヤー・企業別、成長機会別、最新傾向別、開発別、主要な成長ドライバー別、主要な課題別によってセグメンテーション、予測 2028年


[ 英語タイトル ] Pharmaceutical Contract Manufacturing Global Market – Forecast To 2027


Product Code : IQ4IHC00114188
Survey : IQ4I
Publish On : July, 2021
Number of Pages : 531
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4950 / Question Form
5 User USD6750 / Question Form
Enterprise User USD9000 / Question Form
ABBVIE INC.
AENOVA HOLDING GMBH
CARLYLE GROUP (ALBANY MOLECULAR RESEARCH INC)
CHINA RESOURCES PHARMACEUTICALS GROUP LIMITED
FAREVA
LONZA GROUP
PFIZER INC.
PREMIRA FUNDS (CAMBREX CORPORATION U.K.) CORPORATION
RECIPHARM AB (PUBL)
THERMO FISHER SCIENTIFIC
WUXI APPTEC (WUXI STA PHARMACEUTICALS LTD)
LIST OF COMPANIES MENTIONED IN THE REPORT
AARTHI DRUGS LTD
ABBVIE INC.
ACIC PHARMACEUTICALS INC.
ACS DOBFAR
ADARE PHARMACEUTICALS, INC.
AENOVA GROUP GMBH
AESICA PHARMACEUTICALS LTD
AJINOMOTO BIO-PHARMA SERVICES
AKORN
ALEMBIC PHARMACEUTICALS LTD
ALKEM LABORATORIES LTD
ALMAC GROUP
ALPEX PHARMA S.A.
ALPIC REMEDIES LTD
ANGELINI PHARMACEUTICALS
ANI PHARMACEUTICALS
ANTHEM BIOSCIENCES PRIVATE LIMITED
ARAGEN LIFE SCIENCES(GVK BIOSCIENCES PRIVATE LIMITED)
ARDENA HOLDING NV
ARTESAN PHARMA GMBH & CO. KG
ATHENA PHARMACEUTIQUES SAS
AUGUST BIOSERVICES LLC
AUROBINDO PHARMA LIMITED
AVARA PHARMACEUTICAL SERVICES, INC.
BACHEM HOLDING AG
BAHRAIN PHARMA
BERKSHIRE STERILE MANUFACTURING
BIOSIG TECHNOLOGIES (VIRALCLEAR PHARMACEUTICALS)
BIOVECTRA INC.
BIRGIMEFAR GROUP
BSP PHARMACEUTICALS S.P.A
BUSHU PHARMACEUTICALS LTD
CADILA PHARMACEUTICALS LTD
CARLYLE GROUP (ALBANY MOLECULAR RESEARCH INC.)
CASCADE CHEMISTRY
CELLTRION INC.
CERBIOS-PHARMA SA
CHEMCON GMBH
CHINA CHEMICAL & PHARMACEUTICAL CO., LTD
CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED
CIPLA LIMITED
CORDENPHARMA INTERNATIONAL
COSMO PHARMACEUTICALS
DAITO PHARMACEUTICAL CO.,LTD.
DEBIOPHARM GROUP
DELORBIS PHARMACEUTICALS LTD
DELPHARM SAS
DISHMAN (DISHMAN CARBOGEN AMCIS LIMITED)
DOTTIKON EXCLUSIVE SYNTHESIS AG
DR. REDDY'S LABORATORIES LTD
EUROFINS SCIENTIFIC
EVER PHARMA HOLDING GES.M.B.H (EVER NEURO PHARMA GMBH)
EVONIK INDUSTRIES AG
FAREVA GROUP
FLAMMA SPA
FRONTIDA BIOPHARM, INC.
GLAXOSMITHKLINE PLC
GRAND RIVER ASEPTIC MANUFACTURING
GROUP PHARMACEUTICALS LTD
GROUPE PARIMA INC.
HBM PHARMA S.R.O
HELSINN HOLDING S.A. (HELSINN ADVANCED SYNTHESIS SA (HAS))
HERAEUS HOLDING GMBH
HETERO DRUGS LIMITED
HOVIONE
HUNAN HUATENG PHARMACEUTICAL CO. LTD.
INJECTALIA SRL
JEIL PHARMACEUTICAL CO. LTD
JUBILANT LIFESCIENCES
KABI (FRESENIUS KABI CONTRACT MANUFACTURING)
KLEOS PHARMA
KOLMAR KOREA
LABORATORIOS FARMACÉUTICOS ROVI
LANNETT
LGM PHARMA, LLC
LONZA GROUP
LOTUS PHARMACEUTICAL CO., LTD.
LSNE CONTRACT MANUFACTURING
MALLINCKRODT PLC
MARINOPOULOS HOLDING (CYPRUS) LIMITED (FAMAR S.A.)
MEDICEF PHARMA PRIVATE LIMITED
MEDPHARM LTD.
MERCK KGAA
MINAKEM
MOLECULIN BIOTECH
NACTO PHARMA
NEOLPHARMA PHARMACEUTICAL GROUP
NEULAND LABORATORIES LTD.
NEXTPHARMA TECHNOLOGIES HOLDING LIMITED
NIPRO CORPORATION
OLON S.P.A.
OTSUKA PHARMACEUTICAL FACTORY, INC.
PALLADIUM EQUITY PARTNERS
PERMIRA FUNDS (CAMBREX CORPORATION)
PERRIGO COMPANY PLC
PFIZER INC.
PHARMASYNTHESE
PILLAR5 PHARMA INC.
PIRAMAL PHARMA SOLUTIONS
POLYPEPTIDE
PROCOS S.P.A.
QUOTIENT SCIENCES
RECIPHARM AB (PUBL)
REGIS TECHNOLOGIES
ROTTENDORF PHARMA
SAI LIFE SCIENCES
SAMSUNG BIOLOGICS
SANOFI S.A.
SCINOPHARM TAIWAN LTD.
SEIKAGAKU CORPORATION
SEQENS SAS
SHILPA MEDICARE LIMITED
SIEGFRIED HOLDING AG
SK GROUPS (SK BIOPHARMACEUTICALS)
SOLVIAS AG
SOPHARMA PHARMA PLC
STERLING PHARMA SOLUTIONS LIMITED
STRIDES PHARMA SCIENCE LTD
SUN PHARMACEUTICAL INDUSTRIES LTD
SUPRIYA LIFE SCIENCE LTD
TAKEDA PHARMACEUTICAL COMPANY LIMITED
TARO PHARMACEUTICAL INDUSTRIES LTD
TEMAD CO.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
THERMOFISHER SCIENTIFIC (PATHEON N.V.)
UNITHER PHARMACEUTICALS
UPPERTON PHARMA SOLUTIONS
VIATRIS INC. (MYLAN N.V./UPJOHN PFIZER INC.)
WAVELENGTH PHARMACEUTICALS
WUXI APPTEC (WUXI STA PHARMACEUTICALS)
ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD
ZHEJIANG XIANJU PHARMACEUTICAL CO.,LTD.
ZHEJIANG HISUN PHARMACEUTICAL CO. LTD.

[Report Description]

Globally Pharmaceutical markets are showing rapid growth and in coming years expected to evolve further in the field of research and development, manufacturing, and formulation due to rise in population, increase in chronic diseases like infectious diseases, oncology, cardiovascular disorders, rising healthcare expenditures, collaborations, mergers, and acquisitions. Pharmaceutical companies are increasing their dependence on contract manufacturing organizations due to lack of well-equipped manufacturing facilities, advanced technologies, high containment capabilities or though they have the facilities, due to insufficient time and to have backup manufacturing, pharmaceutical companies are outsourcing. This trend is favoring contract manufacturing service providers and is expected to increase the share in the pharmaceutical manufacturing market. Contract pharmaceutical manufacturing services are mainly focused on the manufacturing of Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF).
The pharmaceutical contract manufacturing global market is expected to reach $120,124.7 million by 2027 growing at a high single digit CAGR. Increased trend of outsourcing, high uptake of small molecules drugs across diverse therapeutics, patent expiration of small molecules, advanced technologies in API and FDF manufacturing, increasing deals and investments, increased demand for generic injectables, increasing incidence and prevalence of chronic diseases, and increase in geriatric population are some of the factors driving the market growth. However, contamination of pharmaceutical products (API and FDF), pricing pressure for pharmaceutical contract manufacturing, requirement of highly skilled technicians, increasing biologics approvals and adoption in disease management, stringent regulatory policies, and environmental concerns are some of the factors that are hindering pharmaceutical contract manufacturing global market growth. The pharmaceutical contract manufacturing global market is mainly segmented based on product, phase, application, and geography.
The pharmaceutical contract manufacturing market based on product is segmented into API manufacturing and FDF manufacturing. API manufacturing segment accounted for the largest share in 2020 and FDF manufacturing segment is the fastest growing segment and is expected to grow at high single digit CAGR from 2020 to 2027. The high profit margin for pharma contract manufacturers, shifting from API to FDF manufacturing by CMOs and CDMOs, rising demand for advanced dosage forms, and rising demand for generic drugs are some of the factors driving the growth of the FDF contract manufacturing market.
The API manufacturing market global market based on customer base is sub-segmented into Branded API manufacturing and Generic API manufacturing. The generic API manufacturing segment accounted for the largest revenue in 2020 and is expected to grow at high single digit CAGR from 2020 to 2027, due to the patent expiries of branded drugs, low cost of generic medicines.
The FDF manufacturing global market based on dosage form is further classified into solid dosage form, injectable dosage form, and semi-solid liquid and gaseous dosage form. Solid dosage form segment accounted for the largest revenue in 2020 due to changing consumer demands, advent and progress of newer dosage forms, and ever-evolving regulations. The injectable dosage form is the fastest-growing segment and is expected to grow at a low teen CAGR from 2020 to 2027 due to its direct infusion to the body, ease of administration, and onset of action of drugs is faster as compared to solid dosage forms. Hence it is suitable for emergency conditions. Among semi-solid, liquid, and gaseous dosage form, semisolids segment accounted for the largest revenue of in 2020 owing to the increased usage of semisolids such creams, lotions and gels due to increase in skin related diseases, and changing climatic conditions.
The solid dosage form market is further classified into tablets, capsules, and others such as powders and granules. Among these, tablets segment generated the largest revenue in 2020 owing to its ease of formulation techniques, manufacturing, and ease of administration to all the age groups.
Pharmaceutical contract manufacturing global market based on phase is segmented into commercial manufacturing and clinical manufacturing. Commercial manufacturing segment contributed to the largest revenue in 2020 due to huge demand for commercial API production, patent expiry, and increasing outsourcing of generic APIs. Whereas, clinical manufacturing segment is the fastest growing segment and is expected to grow at high single digit CAGR from 2020 to 2027 owing to a rise in demand for effective novel drugs with various therapeutic applications, rise in R&D investments for discovering new drugs coupled with the rising number of different types of chronic diseases.
The pharmaceutical contract manufacturing market by therapeutic applications is segmented into infectious diseases, oncology, cardiovascular disorders, central nervous system, pulmonary disorder, gastrointestinal disorder, endocrine disorders, metabolic disorders, genito-urinary disorders, musculoskeletal disorders, and others such as others such as ophthalmology, autoimmune diseases, ENT, dental, dermatology, and pain management. Among these applications, the infectious disease segment accounted for the largest revenue in 2020 because of the global-wide rapid spread of COVID-19 and increased incidence of other infectious diseases such as tuberculosis, HIV, pneumonia, influenza, hepatitis, and others. The oncology division is the fastest growing and is expected to grow at a double digit CAGR from 2020 to 2027 driven mainly by the rising incidence of cancer cases, lifestyle changes, increasing geriatric population, high demand for anti-cancer drugs, increase in the usage of synthetic HPAPIs for cancer treatment, increase in geriatric population and rising demand for personalized medicine especially for treating cancer.
The pharmaceutical contract manufacturing market based on region is classified into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (China, India, Japan, and Others), and the Rest of the World (Brazil, Rest of Latin America and Middle East & others). North America accounts for the largest revenue in 2020. The developed healthcare sector, availability of funds, increasing clinical trials, rising burden of cancer, increasing governments focus on generic drugs as well as the establishment of domestic API manufacturers, rising demands for the specialty of drugs and technological advancements, rising demand for advanced dosage forms, and also establishment of foreign CMOs/CDMOs are some of the factors driving the market growth. The Asia-Pacific region is the fastest growing region and is expected to grow at double digit CAGR from 2020 to 2027. Low labor cost, regulatory relaxation, abundance availability of raw materials, infrastructure facility, rise in generic demands, increased production capabilities, the presence of a large number of domestic and international players, coupled with low investments for the establishment of manufacturing facilities as compared to western countries.
Some of the major players are Lonza Group (Switzerland), AbbVie Inc. (AbbVie contract manufacturing, U.S.), Thermo Fisher Scientific (Patheon, N.V., U.S.), Pfizer Inc. (Pfizer CentreOne, U.S.), Permira Funds (Cambrex Corporation, U.K.), Carlyle Group (Albany Molecular Research Inc. U.S.), WuXi AppTec (WuXi STA pharmaceuticals, China), Recipharm AB (publ) (Sweden), Aenova Group GmbH (Germany), China Resources Pharmaceutical Group Limited (China), and others.
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
• North America
o U.S.
o Rest of North America
• Europe
o Germany
o France
o Italy
o Rest of Europe
• Asia-Pacific
o China
o India
o Japan
o Rest of APAC
• Rest of the World (RoW)
o Brazil
o Rest of Latin America
o Middle East and Others


1 EXECUTIVE SUMMARY 23
2 INTRODUCTION 31
2.1 KEY TAKEAWAYS 31
2.2 SCOPE OF THE REPORT 32
2.3 REPORT DESCRIPTION 32
2.4 MARKETS COVERED 36
2.5 STAKEHOLDERS 37
2.6 RESEARCH METHODOLOGY 37
2.6.1 MARKET SIZE ESTIMATION 39
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 42
2.6.3 SECONDARY SOURCES 43
2.6.4 PRIMARY SOURCES 44
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 44
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 46
2.6.7 ASSUMPTIONS 46
3 MARKET ANALYSIS 49
3.1 INTRODUCTION 49
3.2 MARKET SEGMENTATION 51
3.3 FACTORS INFLUENCING MARKET 53
3.3.1 DRIVERS AND OPPORTUNITIES 54
3.3.1.1 Increased trend of outsourcing 54
3.3.1.2 High uptake of small molecules across diverse therapeutics 55
3.3.1.3 Patent expiration of small molecules drugs 57
3.3.1.4 Advanced technologies in API and FDF manufacturing 58
3.3.1.5 Increasing deals and investments 61
3.3.1.6 Generics drive injectable market opportunity 63
3.3.1.7 Increasing chronic diseases 63
3.3.1.8 Increase in geriatric population 65
3.3.2 RESTRAINTS AND THREATS 66
3.3.2.1 Contamination in the manufacturing process (API and FDF) 66
3.3.2.2 Pricing pressure for pharmaceutical contract manufacturing 67
3.3.2.3 Requirement of highly skilled technicians 68
3.3.2.4 Increasing biologics approvals and adoption in disease management 69
3.3.2.5 Stringent regulatory requirements 71
3.4 REGULATORY AFFAIRS 74
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 74
3.4.1.1 ISO 9001: 2015 Quality management system 74
3.4.1.2 ISO 14644-1 Clean room standards 74
3.4.2 U.S. 74
3.4.3 CANADA 77
3.4.4 MEXICO 78
3.4.5 EUROPE 78
3.4.6 JAPAN 80
3.4.7 CHINA 81
3.4.8 INDIA 82
3.4.9 AUSTRALIA 83
3.4.10 SOUTH KOREA 84
3.4.11 LATIN AMERICA 84
3.4.12 MIDDLE EAST 85
3.5 PORTER’S FIVE FORCE ANALYSIS 86
3.5.1 THREAT OF NEW ENTRANTS 87
3.5.2 THREAT OF SUBSTITUTES 87
3.5.3 BARGAINING POWER OF SUPPLIERS 88
3.5.4 BARGAINING POWER OF BUYERS 89
3.5.5 COMPETITIVE RIVALRY 90
3.6 SUPPLY CHAIN ANALYSIS 92
3.7 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 98
3.7.1 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE ANALYSIS 98
3.7.2 MARKET SHARE ANALYSIS OF API MANUFACTURING BY MAJOR
PLAYERS 102
3.7.3 MARKET SHARE ANALYSIS OF FDF MANUFACTURING BY MAJOR
PLAYERS 105
3.8 TECHNOLOGICAL ADVANCEMENTS 107
3.8.1 INTRODUCTION 107
3.8.2 ADVANCED TECHNOLOGIES FOR API MANUFACTURING 107
3.8.3 ADVANCED TECHNOLOGIES FOR FDF MANUFACTURING 113
3.9 DIFFERENTIATED CAPABILITIES 116
3.9.1 HPAPI 119
3.9.1.1 Selected top selling HPAPI 121
3.9.2 CONTINUOUS FLOW MANUFACTURING 122
3.9.3 CRYOGENIC MANUFACTURING PROCESS 124
3.10 CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING MARKET 125
3.11 PATENT EXPIRY AND ANDA APPROVALS 130
3.12 DRUG MASTER FILING (DMF) 145
3.13 COST OF MANUFACTURING FACILITY 150
3.14 FDA APPROVED MANUFACTURING FACILITY 151
3.15 FDA AND EMA APPROVAL DRUGS WITH TYPE OF DOSAGE FORM 153
3.16 NOTICE OF INSPECTIONAL OBSERVATIONS (FORM 483) 155
3.17 IMPACT OF CORONA ON PHARMACEUTICAL CONTRACT MANUFACTURING 157
3.18 COLLABORATION BETWEEN PHARMACEUTICAL COMPANIES AND CONTRACT MANUFACTURERS 158
3.19 COMPANIES ACQUISITION, MERGER AND INVESTMENTS 165
3.20 API PRICING 187
3.21 GLOBAL PHARMACEUTICAL API CMO PRODUCTION VOLUME 190
3.22 CHINA V/S INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET 196
3.22.1 INDIA 196
3.22.2 CHINA 199
3.23 PHARMACEUTICAL CONTRACT MANUFACTURERS REVENUE AND CAPABILITIES TABLE 201
4 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY PRODUCT 219
4.1 INTRODUCTION 219
4.2 API MANUFACTURING 225
4.2.1 BRANDED API MANUFACTURING 229
4.2.2 GENERIC API MANUFACTURING 232
4.3 FINISHED DOSAGE FORM (FDF) MANUFACTURING 234
4.3.1 SOLID DOSAGE FORMS 238
4.3.1.1 Tablets 240
4.3.1.2 Capsules 244
4.3.1.3 Other solid dosage forms (Granules and Powders) 245
4.3.2 INJECTABLES DOSAGE FORMS 248
4.3.3 SEMISOLID, LIQUID AND GASEOUS DOSAGE FORMS 252
4.3.3.1 Semisolids 252
4.3.3.2 Liquids 254
4.3.3.3 Gaseous 257
5 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY PHASE 261
5.1 INTRODUCTION 261
5.2 CLINICAL MANUFACTURING 264
5.3 COMMERCIAL MANUFACTURING 267
6 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY APPLICATION 274
6.1 INTRODUCTION 274
6.2 ONCOLOGY 277
6.3 CENTRAL NERVOUS SYSTEM 282
6.4 CARDIOVASCULAR DISORDERS 286
6.5 INFECTIOUS DISEASES 290
6.6 PULMONARY DISORDERS 297
6.7 METABOLIC DISORDERS 300
6.8 GASTROINTESTINAL DISORDERS 304
6.9 MUSCULOSKELETAL DISORDERS 307
6.10 GENITOURINARY DISORDERS 310
6.11 ENDOCRINOLOGY 313
6.12 OTHER APPLICATIONS (ANESTHESIA, AUTOIMMUNE DISEASES, OPTHALMOLOGY, DENTAL, PAIN MANAGEMENT, GYNAECOLOGY, DERMATOLOGY, AND ENT) 315
7 REGIONAL ANALYSIS 318
7.1 INTRODUCTION 318
7.2 NORTH AMERICA 323
7.2.1 U.S. 336
7.2.2 REST OF NORTH AMERICA 342
7.3 EUROPE 348
7.3.1 GERMANY 361
7.3.2 FRANCE 366
7.3.3 ITALY 370
7.3.4 REST OF EUROPE 374
7.4 APAC 379
7.4.1 CHINA 391
7.4.2 INDIA 398
7.4.3 JAPAN 406
7.4.4 REST OF APAC 412
7.5 ROW 417
7.5.1 BRAZIL 429
7.5.2 REST OF LATAM 432
7.5.3 MIDDLE EAST & OTHERS 437
8 COMPETITIVE LANDSCAPE 441
8.1 INTRODUCTION 441
8.2 ACQUISITION 442
8.3 EXPANSION 445
8.4 AGREEMENTS 448
8.5 SERVICE LAUNCH AND OTHERS 453
9 MAJOR COMPANIES 458
9.1 ABBVIE INC. 458
9.1.1 OVERVIEW 458
9.1.2 FINANCIALS 459
9.1.3 PRODUCT PORTFOLIO 461
9.1.4 KEY DEVELOPMENTS 462
9.1.5 BUSINESS STRATEGY 462
9.1.6 SWOT ANALYSIS 463
9.2 AENOVA HOLDING GMBH 464
9.2.1 OVERVIEW 464
9.2.2 FINANCIALS 465
9.2.3 PRODUCT PORTFOLIO 466
9.2.4 KEY DEVELOPMENTS 466
9.2.5 BUSINESS STRATEGY 468
9.2.6 SWOT ANALYSIS 469
9.3 CARLYLE GROUP (ALBANY MOLECULAR RESEARCH INC) 470
9.3.1 OVERVIEW 470
9.3.2 FINANCIALS 470
9.3.3 PRODUCT PORTFOLIO 471
9.3.4 KEY DEVELOPMENTS 472
9.3.5 BUSINESS STRATEGY 473
9.3.6 SWOT ANALYSIS 475
9.4 CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED 476
9.4.1 OVERVIEW 476
9.4.2 FINANCIALS 477
9.4.3 PRODUCT PORTFOLIO 479
9.4.4 KEY DEVELOPMENTS 479
9.4.5 BUSINESS STRATEGY 479
9.4.6 SWOT ANALYSIS 480
9.5 FAREVA SA 481
9.5.1 OVERVIEW 481
9.5.2 FINANCIALS 481
9.5.3 PRODUCT PORTFOLIO 482
9.5.4 KEY DEVELOPMENTS 483
9.5.5 BUSINESS STRATEGY 483
9.5.6 SWOT ANALYSIS 484
9.6 LONZA GROUP LTD 485
9.6.1 OVERVIEW 485
9.6.2 FINANCIALS 486
9.6.3 PRODUCT PORTFOLIO 489
9.6.4 KEY DEVELOPMENTS 490
9.6.5 BUSINESS STRATEGY 491
9.6.6 SWOT ANALYSIS 492
9.7 PFIZER INC. 493
9.7.1 OVERVIEW 493
9.7.2 FINANCIALS 494
9.7.3 PRODUCT PORTFOLIO 497
9.7.4 KEY DEVELOPMENTS 497
9.7.5 BUSINESS STRATEGY 498
9.7.6 SWOT ANALYSIS 499
9.8 PERMIRA FUNDS (CAMBREX CORPORATION U.K.) CORPORATION 500
9.8.1 OVERVIEW 500
9.8.2 FINANCIALS 501
9.8.3 PRODUCT PORTFOLIO 501
9.8.4 KEY DEVELOPMENTS 503
9.8.5 BUSINESS STRATEGY 505
9.8.6 SWOT ANALYSIS 506
9.9 RECIPHARM AB 507
9.9.1 OVERVIEW 507
9.9.2 FINANCIALS 508
9.9.3 PRODUCT PORTFOLIO 511
9.9.4 KEY DEVELOPMENTS 512
9.9.5 BUSINESS STRATEGY 513
9.9.6 SWOT ANALYSIS 515
9.10 THERMO FISHER SCIENTIFIC INC 516
9.10.1 OVERVIEW 516
9.10.2 FINANCIALS 517
9.10.3 PRODUCT PORTFOLIO 520
9.10.4 KEY DEVELOPMENTS 521
9.10.5 BUSINESS STRATEGY 522
9.10.6 SWOT ANALYSIS 523
9.11 WUXI APPTEC (WUXI STA PHARMACEUTICALS LTD) 524
9.11.1 OVERVIEW 524
9.11.2 FINANCIALS 525
9.11.3 PRODUCT PORTFOLIO 527
9.11.4 KEY DEVELOPMENTS 528
9.11.5 BUSINESS STRATEGY 529
9.11.6 SWOT ANALYSIS 530

LIST OF FIGURES
FIGURE 1 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN) 30
FIGURE 2 RESEARCH METHODOLOGY: PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET 39
FIGURE 3 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET:
TOP-DOWN AND BOTTOM-UP APPROACH 40
FIGURE 4 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: FORECASTING MODEL 41
FIGURE 5 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET:
MARKET BREAKDOWN AND DATA TRIANGULATION 42
FIGURE 6 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SEGMENTATION 52
FIGURE 7 MARKET DYNAMICS 53
FIGURE 8 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: PORTER’S ANALYSIS 86
FIGURE 9 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET:
SUPPLY CHAIN ANALYSIS 92
FIGURE 10 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%) 98
FIGURE 11 API MANUFACTURING GLOBAL MARKET SHARE ANALYSIS,
BY KEY PLAYERS, 2020 (%) 102
FIGURE 12 FDF MANUFACTURING GLOBAL MARKET SHARE ANALYSIS,
BY KEY PLAYERS, 2020 (%) 105
FIGURE 13 CONTRACT MANUFACTURING COMPANY CAPABILITIES 118
FIGURE 14 CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING REVENUE,
BY MARKET, 2020 ($MN) 129
FIGURE 15 PATENT EXPIRY OF SMALL MOLECULES (2018-2025) 132
FIGURE 16 PATENT EXPIRY (2018-2025) AND ANDA APPROVALS (2020-2021),
BY APPLICATION SHARE (%) 133
FIGURE 17 API DMF FILED BY COUNTRIES (2020) (NO’S) 148
FIGURE 18 API DMF FILED, BY COMPANY (2020) (NO’S) 149
FIGURE 19 FDA APPROVED GLOBAL API MANUFACTURING LANDSCAPE (2020) 152
FIGURE 20 FDA AND EMA APPROVED DRUGS AND FORMULATION TYPE (2020 – 2021) 154
FIGURE 21 FORM 483 NON-COMPLIANCE, BY COUNTRY (2020) (NO’S) 156
FIGURE 22 PHARMACEUTICAL API PRODUCTION BY APPLICATION (2020),
IN-HOUSE V/S CMO (2019 – 2027) (TONS) AND GLOBAL MANUFACTURING CAPACITIES (2020) (LITRES) 193
FIGURE 23 GLOBAL PHARMACEUTICAL API CMO PRODUCTION (2019 – 2027) (TONS), API CMO MARKET SHARE BY REGION (2020) (%) 194
FIGURE 24 INDIA V/S CHINA 196
FIGURE 25 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%) 222
FIGURE 26 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%) 224
FIGURE 27 API MANUFACTURING GLOBAL MARKET SHARE, BY CUSTOMER BASE (2020 V/S 2027) (%) 227
FIGURE 28 FDF MANUFACTURING GLOBAL MARKET SHARE, BY DOSAGE FORM,
(2020 V/S 2027) (%) 236
FIGURE 29 SOLID DOSAGE FORM CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY DOSAGE TYPE, (2020) (%) 248
FIGURE 30 SEMI-SOLID, LIQUID, AND GASEOUS DOSAGE FORM CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY DOSAGE FORM, (2020) (%) 260
FIGURE 31 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY PHASE (2020 V/S 2027) (%) 263
FIGURE 32 COMMERCIAL MANUFACTURING GLOBAL MARKET SHARE,
BY REGION, (2020 V/S 2027) (%) 273
FIGURE 33 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 276
FIGURE 34 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN), CAGR (%) 321
FIGURE 35 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY GEOGRAPHY (2020) (%) 322
FIGURE 36 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT AND BY PHASE (2020 V/S 2027) (%) 331
FIGURE 37 NORTH AMERICA PHARMACEUTICAL CONTRACT API AND FDF MANUFACTURING MARKET SHARE, BY CUSTOMER BASE AND BY DOSAGE FORM (2020 V/S 2027) (%) 332
FIGURE 38 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 333
FIGURE 39 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2020 V/S 2027) (%) 335
FIGURE 40 U.S. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE,
BY PRODUCT (2020 V/S 2027) ($MN) 340
FIGURE 41 U.S. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE,
BY APPLICATION (2020 V/S 2027) ($MN) 341
FIGURE 42 REST OF NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN) 346
FIGURE 43 REST OF NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 347
FIGURE 44 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT AND BY PHASE (2020 V/S 2027) (%) 356
FIGURE 45 EUROPE PHARMACEUTICAL CONTRACT API AND FDF MANUFACTURING MARKET SHARE, BY CUSTOMER PHASE AND BY DOSAGE FORM
(2020 V/S 2027) (%) 357
FIGURE 46 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 358
FIGURE 47 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING SHARE,
BY COUNTRY (2020 V/S 2027) (%) 360
FIGURE 48 GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN) 364
FIGURE 49 GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN) 365
FIGURE 50 FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN) 368
FIGURE 51 FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN) 369
FIGURE 52 ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN) 372
FIGURE 53 ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN) 373
FIGURE 54 REST OF EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN) 377
FIGURE 55 REST OF EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN) 378
FIGURE 56 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE,
BY PRODUCT AND BY PHASE (2020 V/S 2027) (%) 386
FIGURE 57 APAC PHARMACEUTICAL CONTRACT API AND FDF MANUFACTURING MARKET SHARE BY CUSTOMER BASE AND DOSAGE FORM (2020 V/S 2027) (%) 387
FIGURE 58 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE,
BY APPLICATION (2020 VS 2027) (%) 388
FIGURE 59 APAC PHARMACEUTICAL CONTRACT MANUFACTURING SHARE,
BY COUNTRY (2020 V/S 2027) (%) 390
FIGURE 60 CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN) 396
FIGURE 61 CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN) 397
FIGURE 62 INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN) 404
FIGURE 63 INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN) 405
FIGURE 64 JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN) 410
FIGURE 65 JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN) 411
FIGURE 66 REST OF APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN) 415
FIGURE 67 REST OF APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN) 416
FIGURE 68 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE,
BY PRODUCT, BY PHASE (2020 V/S 2027) (%) 424
FIGURE 69 ROW PHARMACEUTICAL CONTRACT API AND FDF MANUFACTURING MARKET BY CUSTOMER BASE AND BY DOSAGE FORMS (2020 V/S 2027) (%) 425
FIGURE 70 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE,
BY APPLICATION (2020) (%) 426
FIGURE 71 ROW PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2020 V/S 2027) (%) 428
FIGURE 72 BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN) 431
FIGURE 73 BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN) 432
FIGURE 74 REST OF LATAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN) 435
FIGURE 75 REST OF LATAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN) 436
FIGURE 76 MIDDLE EAST & OTHERS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN) 439
FIGURE 77 MIDDLE EAST & OTHERS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN) 440
FIGURE 78 KEY GROWTH STRATEGIES, (2019-2021) 441
FIGURE 79 SWOT: ABBVIE INC. 463
FIGURE 80 SWOT: AENOVA HOLDING GMBH 469
FIGURE 81 SWOT: CARLYLE GROUP (ALBANY MOLECULAR RESEARCH INC) 475
FIGURE 82 SWOT: CHINA RESOURCES PHARMACEUTICALS GROUP LIMITED 480
FIGURE 83 SWOT: FAREVA 484
FIGURE 84 SWOT: LONZA GROUP 492
FIGURE 85 SWOT: PFIZER INC. 499
FIGURE 86 SWOT: PREMIRA FUNDS (CAMBREX CORPORATION U.K.) CORPORATION 506
FIGURE 87 SWOT: RECIPHARM AB (PUBL) 515
FIGURE 88 SWOT: THERMO FISHER SCIENTIFIC 523
FIGURE 89 SWOT: WUXI APPTEC (WUXI STA PHARMACEUTICALS LTD) 530

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+